IMV Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Careers
    • Overview
    • Life at IMV
  • The DPX™ Platform
    • Overview
    • Scientific Publications & Posters
  • Clinical Pipeline
    • Overview
    • Maveropepimut-S
    • DPX-RSV
    • DPX-COVID-19
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contact Us
    • FAQ
  • Contact
    • Get in Touch
    • Safety & Respect

Press Releases

News & Events

News & Events

  • Press Releases
  • Events
  • Email Alerts
Dec 06, 2020 8:15am EST

Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

Dec 03, 2020 7:10am EST

IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer

Nov 13, 2020 7:05am EST

IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy

Nov 12, 2020 7:05am EST

IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update

Nov 10, 2020 7:05am EST

IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer

Nov 09, 2020 5:05pm EST

IMV to Participate in Two Upcoming Investor Conferences

Nov 09, 2020 8:00am EST

IMV’s T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL

Nov 04, 2020 5:05pm EST

Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV’s T Cell Therapy in Combination With Merck’s Keytruda® in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting

Oct 29, 2020 7:05am EDT

IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy

Oct 16, 2020 4:48pm EDT

IMV Inc. Re-establishes At-the-Market Facility

RSS
  • Prev
  • 1...
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • ...42
  • Next
IMV Inc.
About Us Careers The DPX™ Platform Clinical Pipeline News & Events Investors Contact
Twitter LinkedIn Youtube
© 2023 IMV Inc. All Rights Reserved.
Privacy Policy Terms of Use Sitemap